Neuroleptic treatment of agitation and psychosis in dementia.
Neuroleptics remain the mainstay for the treatment of behavioral disturbance and psychotic symptoms in demented patients. The limited available data suggest that low-dose neuroleptics are significantly more efficacious than placebo, though the magnitude of the effect is moderate in most published studies. Demented patients are particularly prone to neuroleptic side effects, and individualized dose titration may be necessary to achieve the optimal trade-off between efficacy and side effects. Target behavioral symptoms and side effects, including effects on cognition and activities of daily life, should be identified and assessed serially during neuroleptic treatment. The choice of neuroleptic depends more on likely side effects than differential efficacy, and non-response or intolerable side effects should lead to dose adjustment or a switch to an alternative class of neuroleptic (or an alternative type of medication). Further studies of optimal neuroleptic dosage, the optimal duration of continuation neuroleptic treatment, and placebo-controlled studies comparing neuroleptics to other classes of medications are needed.
Devanand
D P
DP
Memory Disorders Center, Columbia University, New York, New York 10032, USA.
Levy
S R
SR
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003702:Delusions / Q000188:drug therapy; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D011595:Psychomotor Agitation / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents